Antipsychotics (Segars) Flashcards
main difference between 1st gen agents (conventional/typical) vs 2nd gen agents (novel/atypical)? BIG STAR
Reduction in movement-disorder Side effects
chlorpromazine, fluphenazine, haloperidol, thioridazine, and thiothexine are __ antipsychotics
1st gen/conventional/typical
aripiprazole, clozapine, olanzapine, quetiapine, risperidone, and ziprasidone are __ antipsychotics
2nd gen/novel/atypical
if an antipsychotic end in -AZINE, it is a __ generation
if an antipsychotic ends in -PIPRAZOLE, -APINE, or -IDONE, it is a __ generation
1st
2nd
recurrent suicidal behavior can be tx with __
clozapine (2nd gen)
__ antagonists reduce positive symptoms of schizophrenia (hallucinations, delusions, disorganized speech/thinking, agitation, abnormal motor behavior)
D2
2 dopamine pathways relevant to schizophrenia symptoms?
Mesolimbic –> overactivity –> positive symptoms
Mesocortical –> dysfunction –> negative and cognitive symptoms
D2 antagonism of Nigrostriatal pathway induces __ symptoms
extrapyramidal
D2 antagonism effects on prolactin levels?
increases prolactin levels
the FGA’s primarily block __ receptors
D2 post-synaptic
block D2»_space; 5HT2
other receptors that FGAs also block (with varying potencies)?
Muscarinic –> anti-cholinergic SE’s
H1 receptors –> Sedation SE
a1 receptors –> Orthostatic hypotension, dizziness/syncope SE’s
D2 in nigrostriatal (movements) and tuberoinfundibular (prolactin)
can get risk of QTc prolongation and seizure activity
Treatment for acute dystonia/akathisia/dyskinesia/parkinsonism-like SEs from using FGA’s? BIG STAR
Anticholingeric agents: Diphenhydramine (benadryl), benztropine (cogentin), and trihexyphenidyl
what are the high potency FGAs that cause more movement (EPS) and endocrine effects (prolactin)?
Fluphenazine
Haloperidol
Thiothixene
SGA’s block what receptors?
D2 post-synaptic AND 5HT2a
5-HT2a»_space; D2
what is the dual 5-HT2a/D2 theory?
5-HT2a antagonism increases DA transmission in nigrostriatal pathway –> may contribute to improved negative and cognitive symptoms via increased DA release in PFC, reduced EP SE’s